Kelun Group

Sichuan Kelun Pharmaceutical is a leading Chinese pharmaceutical group that has evolved from a dominant player in the intravenous (IV) infusion market to a global innovator in oncology. Through its subsidiary Kelun-Biotech, the company has developed a world-class Antibody-Drug Conjugate (ADC) platform known as OptiDC, which has facilitated landmark licensing agreements with Merck & Co. (MSD). Their robust pipeline includes several late-stage candidates targeting TROP2, HER2, and PD-L1, positioning them as a key competitor in the next generation of cancer therapeutics. Beyond oncology, Kelun maintains a massive manufacturing footprint for generic drugs, antibiotics, and parenteral nutrition, serving both domestic and international markets.